COVID-19 therapeutics.
Daniele FocosiMassimo FranchiniFabrizio MaggiShmuel ShohamPublished in: Clinical microbiology reviews (2024)
SUMMARYSince the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options has been studied and deployed. Healthcare providers have multiple treatment approaches to choose from, but efficacy of those approaches often remains controversial or compromised by viral evolution. Uncertainties still persist regarding the best therapies for high-risk patients, and the drug pipeline is suffering fatigue and shortage of funding. In this article, we review the antiviral activity, mechanism of action, pharmacokinetics, and safety of COVID-19 antiviral therapies. Additionally, we summarize the evidence from randomized controlled trials on efficacy and safety of the various COVID-19 antivirals and discuss unmet needs which should be addressed.
Keyphrases
- sars cov
- coronavirus disease
- healthcare
- randomized controlled trial
- end stage renal disease
- respiratory syndrome coronavirus
- newly diagnosed
- ejection fraction
- small molecule
- peritoneal dialysis
- emergency department
- systematic review
- social media
- health insurance
- sleep quality
- smoking cessation
- patient reported
- replacement therapy